

Peter R. Thomsen

epi President, European Patent Institute

Before becoming epi President in 2023, Peter was Chair of the epi Litigation Committee and epi Treasurer. As delegate he represents epi as observer at the UPC Administrative Committee. Peter is a European and a Swiss Patent Attorney, and he has been working in the Intellectual Property Function in the Healthcare Industry from 2001 to 2024 where he became involved in a considerable number of questions around regulatory exclusivities and Patent Term Extensions, including SPC Cases up to the level of CJEU. Since 2012 he has been focusing on IP-policy work. He studied biotechnological sciences at the Technical University Braunschweig (Germany), acquired Diploma in European Patent Litigation by CEIPI and holds the EQE. He regularly gives lectures and is a co-author of several books in the patent field.

Alexander Meier

Life Sciences Regulatory Partner at Morgan Lewis

Dr. Alexander Meier is a German trained lawyer and admitted to the German Bar since 2000. He has more than 25 years of relevant professional experience as an external attorney and in-house lawyer in the field of pharmaceutical law. Alexander Meier is specialized in European and German regulatory law relating to chemical and biological pharmaceuticals (including advanced therapies) and medical devices. He advises and represents national and international pharmaceutical and medical device companies in all areas of pharmaceutical law (including GxP and Medical Affairs), competition law and compliance-related aspects. A particular specialization is given in the field of biopharmaceuticals, in particular advanced therapy medicinal products (ATMPs) and vaccines, as well as in the area of regulatory exclusivity rights with extensive practical experience.



Alexander Meier joined Morgan Lewis as Life Sciences Regulatory Partner in their Munich Office in February 2026. Before, Alexander Meier worked for Moderna in Basel since October 2023 as Head Legal Regulatory Strategy and Global Regulatory Policy. Prior to that, he had been with Preu Bohlig in Munich as Partner since January 2019 and with Hoyng Rokh Monegier in Amsterdam and Munich since May 2017. Before, Alexander Meier worked as inhouse attorney for Novartis for 11 years with increasing responsibilities, first for the Generics Division in Holzkirchen (DE) as Head of Legal and Compliance Officer for Sandoz/Hexal Germany and thereafter in the Group Headquarters in Basel (CH), amongst others as Global Head, Legal of TechOps, Regulatory and Development for the Originator Division of Novartis Pharma and as Head of Legal, Global and Pharma Drug Development for Novartis across all Divisions. Before that, he already worked as external counsel in Munich in two pharmaceutical law firm

boutiques from 2000 until 2006. Alexander Meier is the author of numerous publications and a regular speaker at international conferences.

He is co-editor and author of the second edition of the textbook “Pharmarecht”, in 2023 published in 3rd edition. He was a lecturer at the Philipps-Universität Marburg in the Master’s programme “Pharma Law LL.M.”, at the European Center of Pharmaceutical Medicine (ECPM) of the University of Basel (CH) and still is at the CEIPI of the University of Strasbourg (FR).

Pierick Rousseau

Lifesciences and Cosmetic IP expert

Former IP Director Pierre Fabre Group

European and French patent Attorney

UPC representative



Pierick Rousseau has been the Head of the IP department of the French group Pierre Fabre from 2006 to 2021. Pierre Fabre’s product portfolio ranges from prescription drugs, to consumer healthcare products and dermo-cosmetics. Before, Pierick occupied various patent functions in the leading life sciences company in France, Sanofi Group (and its predecessors Roussel-UCLAF, Hoechst Marion Roussel and Aventis).

Since end of 2023 Pierick has developed a new consulting business in IP and notably works with McArthur&associates based in Basel and Légapole Avocat Cabinet Pantz based in Toulouse.

Pierick trained in organic chemistry (Engineer CNAM, Paris) and is an European and French Patent attorney and most recently UPC representative. He is also a graduated of the Business Leadership Program at Ashridge Business School, UK.

At Pierre Fabre, Pierick was in charge of trademarks, patents, domain names, and anti-counterfeiting. It also manages a high level of business development activity. Pierick has developed a sophisticated inventorship compensation program and had updated the IP management system with Anaqua®.

During Pierre Fabre activity, Pierick has been President of the Patent Group within the LEEM (Pharmaceutical Industry Association) for more than 10 years and has been a member of the IPEG group of EFPIA (European Federation of Pharmaceutical Industries Associations) and IP group of G5 Santé. He has been involved in mixed private and public commissions (CSIS/CSF).

Pierick Rousseau is still involved in IP activities as board member of ASPI, board member of IEEPI, Investment Committee of SATT Aquitaine and lectures on pharmaceutical patents at the law universities of Toulouse, Aix, and Montpellier and at University of Pharmacy of Montpellier. Pierick is or has been a member of several professional associations (EPI (substitute member of the council) , AIPPI, APRAM, INTA, UNIFAB, LES, EPITOUL, AFPPI and EDIPI). At last he is member of the Jury for the French Patent qualification examination (INPI).

Pierick regularly addressed international conferences sponsored by AFPI in Tokyo, Osaka (Japan), Medellín and Bogotá (Colombia), and Abu Dhabi (United Arab Emirates). On behalf of INPI, He also contributed to a couple of IP Masterclasses and coaching for small and mid-size companies (Bordeaux, Nantes and Santiago, Chile).

Anne Boutaric

European and French patent attorney, Germain Maureau

Chairwoman of the SPC group within the French patent attorneys organization (CNCPI), Anne Boutaric is a French and European patent attorney graduated in chemistry and in IP Law. After 22 years in a one of the top 5 French IP law firm, Anne joined Germain Maureau in 2025. With the Germain Maureau teams, she is advising French and foreign companies, including start-ups, universities, medium size companies and international corporations. Anne is involved on a regular basis in patent and supplemental protection certificate (SPC) litigations in pharma, including French disputes conducted in parallel with other pan-European litigations. Anne has developed a large experience in filing and prosecuting SPCs in France. She closely follows legislative and jurisprudential developments of SPC system whose optimization is one of the top priorities of the EU Commission.